Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
:CGON
Holding CGON?
Track your performance easily
CGON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.77 - $50.23
Previous Close$30.46
Volume740.02K
Average Volume (3M)912.97K
Market Cap
$2.22B
Enterprise Value$2.01B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding76,129,680
10 Day Avg. Volume731,126
30 Day Avg. Volume912,967
Standard Deviation0.11
R-Squared0.14
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2927.65
Price to Cash Flow (P/CF)-31.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$67.33Price Target Upside131.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
CG Oncology, Inc. News
PremiumCompany Announcements
CG Oncology Amends Key Executive Employment AgreementsPremiumCompany Announcements
CG Oncology Reports Promising Phase 3 Trial ResultsBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsCretostimogene demonstrated sustained durations of response in HR BCG-unresponsive NMIBC, with an estimated 12-month DoR probability of 63.5% and a 24-month DoR probability of 56.6%.
Efficacy And SafetyCretostimogene's safety profile shows zero Grade 3+ treatment-related adverse events and zero discontinuation rate, which is more favorable compared to TAR-200.
Regulatory And Commercial ProspectsThe company is on track to file for regulatory approval with a potential commercial launch, positioning cretostimogene for success in the market.
Bears Say
Investor ConcernsSome investors have concerns about the ease of use of the treatment compared to competitors, particularly in terms of handling and storage requirements.
Market PositionThe ongoing BCG shortages and hesitancy among community urologists to adopt immune-oncology therapies are expected to limit the near-term impact of the CREST study on cretostimogene's market position.
Treatment AdoptionThe ongoing BCG shortages and hesitancy among community urologists to adopt immune-oncology therapies limit the near-term impact of new treatments.
---
Ownership Overview
29.42% Insiders
11.07% Mutual Funds
0.03% Other Institutional Investors
48.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $25.77 and its highest was $50.23 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $2.22B.
When is CG Oncology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Aug 08, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.356 by $0.076.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 76,129,680 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.356. Following the earnings report the stock price went down -6.828%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
---
CG Oncology, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.33 (131.37% Upside)
$67.33 (131.37% Upside)
Blogger Sentiment
Neutral
CGON Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 590.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
CG Oncology, Inc.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life.
---
CGON Stock 12 Month Forecast
Average Price Target
$67.33
▲(131.37% Upside)
Technical Analysis
Best Analysts Covering CGON
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-18.80%
reiterated a buy rating 8 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -18.80% per trade.
---